#1 Clinical Trials Search in Europe

Kbp-336

A new clinical trial is underway to assess the effectiveness and safety of KBP-336, a potential treatment for individuals living with obesity and knee osteoarthritis. This study aims to determine if KBP-336 can reduce knee pain and promote weight loss in this population. The trial will compare KBP-336 to a placebo over a 6-month period, focusing on pain reduction, weight loss, and overall quality of life improvements.

Table of Contents

What is KBP-336?

KBP-336 is a new investigational drug being studied for the treatment of knee osteoarthritis in obese individuals. It is currently undergoing a Phase IIa clinical trial to evaluate its effectiveness and safety[1]. KBP-336 is administered as a solution for injection, given subcutaneously (under the skin)[1].

Target Condition: Knee Osteoarthritis in Obese Individuals

The study focuses on individuals who have both knee osteoarthritis and obesity. Osteoarthritis is a condition where the protective cartilage in joints breaks down, causing pain and stiffness. Obesity can worsen osteoarthritis by putting extra stress on the knee joints[1].

How KBP-336 Works

While the exact mechanism of KBP-336 is not fully described in the provided information, it is classified as a protein-based medication[1]. The study aims to investigate how KBP-336, when used alongside diet and exercise, might help with weight loss and reduce pain associated with knee osteoarthritis[1].

Clinical Trial Details

The ongoing clinical trial for KBP-336 is described as a double-blind, placebo-controlled, randomized study. This means that:

  • Some participants will receive KBP-336, while others will receive a placebo (a substance with no active ingredients)
  • Neither the participants nor the researchers know who is receiving the actual drug or the placebo
  • Participants are randomly assigned to either the KBP-336 group or the placebo group
This design helps ensure that the results of the study are as unbiased as possible[1].

Potential Benefits of KBP-336

The study aims to evaluate several potential benefits of KBP-336, including:

  • Reduction in body weight
  • Decrease in knee pain related to osteoarthritis
  • Improvement in other osteoarthritis symptoms, such as stiffness and function
  • Enhancement of overall quality of life
  • Changes in body composition, including fat, lean, and bone mass
These outcomes will be measured and compared between the KBP-336 and placebo groups to determine the drug’s effectiveness[1].

Eligibility Criteria

To participate in the KBP-336 clinical trial, individuals must meet specific criteria, including:

  • Age 45 or older
  • Body Mass Index (BMI) of 30 kg/m² or higher
  • Diagnosed with knee osteoarthritis for at least 3 months
  • Willing to follow the study requirements, including diet and exercise recommendations
  • Not having had certain treatments, such as knee surgery or specific injections, within a certain timeframe
There are also several exclusion criteria, such as certain medical conditions or treatments that would prevent participation[1].

Safety Considerations

As with any clinical trial, the safety of participants is a top priority. The study will carefully monitor participants for any side effects or adverse reactions to KBP-336. Participants will be required to discontinue certain pain medications during the trial, except for a limited amount of paracetamol as a rescue medication[1].

It’s important to note that KBP-336 is still an investigational drug, and its full safety profile is not yet known. The clinical trial aims to gather more information about both its effectiveness and potential risks[1].

Aspect Details
Study Drug KBP-336 (Dual Amylin and Calcitonin Receptor agonist)
Administration Weekly subcutaneous injection
Target Population Obese individuals with knee osteoarthritis
Study Duration 6 months (183 days)
Primary Outcomes Change in body weight, Change in WOMAC pain scale
Secondary Outcomes Changes in WOMAC stiffness and function, Quality of life (AQoL 8D), Body composition, Bone mineral density
Study Design Double-blind, Randomized, Placebo-controlled trial

FAQ

  • What is KBP-336? KBP-336 is a long-acting Dual Amylin and Calcitonin Receptor agonist designed for weekly administration through subcutaneous injection. It is being studied as a potential treatment for obese individuals with knee osteoarthritis.
  • How long does the clinical trial last? The clinical trial lasts for 6 months (183 days). Participants will take KBP-336 or a placebo every week during this period and visit the clinic once every 2 weeks for checkups and tests.
  • What are the main goals of this clinical trial? The main goals are to determine if KBP-336 can lower knee pain from osteoarthritis in individuals with obesity and if it can help reduce body weight in the same population. The study will also assess the drug's effects on quality of life and metabolism, as well as its overall safety.
  • How will the effectiveness of KBP-336 be measured? The effectiveness will be measured using various tools, including the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) for pain, stiffness, and function, body weight changes, and the Assessment of Quality of Life 8 Dimensions (AQoL 8D) questionnaire. The study will also track changes in body composition and bone mineral density.
  • What is a placebo and why is it used in this trial? A placebo is a look-alike substance that contains no active drug. In this trial, some participants will receive a placebo instead of KBP-336. This helps researchers compare the effects of KBP-336 to no treatment, allowing them to determine if the drug is truly effective.

Ongoing Clinical Trials on Kbp-336

  • Study on the Effects of KBP-336 and Paracetamol for Obese Patients with Knee Osteoarthritis

    Not recruiting

    2 1 1
    Investigated drugs:
    Czechia Denmark Poland Romania

Glossary

  • Osteoarthritis: A type of joint disease that results from breakdown of joint cartilage and underlying bone, causing pain and stiffness.
  • Subcutaneous injection: A method of administering medication by injecting it into the layer of fat just beneath the skin.
  • WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index): A widely used set of standardized questionnaires to evaluate the condition of patients with osteoarthritis of the knee and hip, including pain, stiffness, and physical functioning of the joints.
  • AQoL 8D (Assessment of Quality of Life 8 Dimensions): A questionnaire that measures health-related quality of life across eight dimensions, including happiness, coping, self-worth, relationships, and mental health.
  • DXA (Dual-energy X-ray Absorptiometry): A medical imaging technique used to measure bone density and body composition.
  • Numerical Rating Scale (NRS): A pain assessment tool where patients rate their pain on a scale from 0 (no pain) to 10 (worst pain imaginable).
  • Dual Amylin and Calcitonin Receptor agonist: A type of drug that activates both amylin and calcitonin receptors, potentially affecting metabolism and pain perception.
  • Double-blind study: A research design where neither the participants nor the researchers directly involved know who is receiving the treatment and who is receiving the placebo.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-kbp-336-and-paracetamol-for-obese-patients-with-knee-osteoarthritis/